Related Experiment Videos
Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial
L L Greenhill1, J M Swanson, B Vitiello
1Clinical Psychiatry, Department of Psychiatry, Columbia University, New York, USA. LarryLGreenhill@cs.com
Insights
The Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder (ADHD) found that a controlled methylphenidate (MPH) titration effectively identified optimal ADHD medication doses for children, showing significant improvements in behavior. This study confirmed MPH efficacy and established dosing guidelines.
Area of Science:
- Child and Adolescent Psychiatry
- Neurodevelopmental Disorders
- Pharmacological Treatments
Background:
- Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder in children.
- Methylphenidate (MPH) is a widely prescribed stimulant medication for ADHD management.
- Optimizing MPH dosage is crucial for maximizing treatment efficacy and minimizing adverse effects.
Purpose of the Study:
- To evaluate the effectiveness of a double-blind, placebo-controlled methylphenidate (MPH) titration protocol in determining the optimal MPH dose for children with ADHD.
- To analyze the impact of different MPH doses on behavioral outcomes as rated by teachers and parents.
Main Methods:
- The study involved 289 children with ADHD assigned to medication treatment groups within the NIMH Collaborative Multisite Multimodal Treatment Study (MTA).
- Participants underwent a 28-day controlled titration protocol, receiving placebo, low, middle, and high doses of MPH on successive days.
- Teacher and parent ratings were used to assess behavioral impairment and deportment.
Main Results:
- A significant main effect of MPH dose was observed, with greater improvements in teacher-reported impairment and deportment compared to parent ratings.
- Effect sizes for MPH dose on teacher ratings ranged from 0.8-1.3, while on parent ratings, they ranged from 0.4-0.6.
- No significant interactions were found between MPH dose and other factors like treatment period, dose order, comorbid diagnoses, study site, or treatment group.
Conclusions:
- The MTA titration protocol successfully validated the efficacy of MPH dosing, including weekend administration.
- A total daily dose limit of 35 mg of MPH was established for children weighing less than 25 kg.
- The study replicated previous findings on MPH response rates (77%), optimal dose distribution (10-50 mg/day), and dose-related adverse events.
Objective:
Results of the NIMH Collaborative Multisite Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder (MTA) were analyzed to determine whether a double-blind, placebo-controlled methylphenidate (MPH) titration trial identified the best MPH dose for each child with attention-deficit/hyperactivity disorder (ADHD).
Method:
Children with ADHD assigned to MTA medication treatment groups (n = 289) underwent a controlled 28-day titration protocol that administered different MPH doses (placebo, low, middle, and high) on successive days.
Results:
A repeated-measures analysis of variance revealed main effects for MPH dose with greater effects on teacher ratings of impairment and deportment (F3 = 100.6, n = 223, p = .0001; effect sizes 0.8-1.3) than on parent ratings of similar endpoints (F3 = 55.61, n = 253, p = .00001; effect sizes 0.4-0.6). Dose did not interact with period, dose order, comorbid diagnosis, site, or treatment group.
Conclusions:
The MTA titration protocol validated the efficacy of weekend MPH dosing and established a total daily dose limit of 35 mg of MPH for children weighing less than 25 kg. It replicated previously reported MPH response rates (77%), distribution of best doses (10-50 mg/day) across subjects, effect sizes on impairment and deportment, as well as dose-related adverse events.